203 related articles for article (PubMed ID: 27742771)
1. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
2. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
3. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
4. Impact of Notch disruption on myeloid development.
Francis OL; Chaudhry KK; Lamprecht T; Klco JM
Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212
[No Abstract] [Full Text] [Related]
5. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Rampal R; Levine RL
Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
7. ZBTB7A links tumor metabolism to myeloid differentiation.
Redondo Monte E; Kerbs P; Greif PA
Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064
[TBL] [Abstract][Full Text] [Related]
8. Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
Hu AY; Zhou T
Br J Haematol; 2019 Jan; 184(1):8. PubMed ID: 30407632
[No Abstract] [Full Text] [Related]
9. Platelet miR-28 expression level and thrombocytosis in MPN patients.
Stolyar MA; Gorbenko AS; Olkhovskiy IA
Int J Lab Hematol; 2019 Apr; 41(2):e43-e45. PubMed ID: 30480878
[No Abstract] [Full Text] [Related]
10. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
[No Abstract] [Full Text] [Related]
11. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
[No Abstract] [Full Text] [Related]
12. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
Patterson-Fortin J; Moliterno AR
Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
[TBL] [Abstract][Full Text] [Related]
14. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
Zhang J; Fleischman AG; Wodarz D; Komarova NL
J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
16. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
[TBL] [Abstract][Full Text] [Related]
17. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
18. The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2.
Siegwart LC; Schwemmers S; Wehrle J; Koellerer C; Seeger T; Gründer A; Pahl HL
Exp Hematol; 2020 Jul; 87():42-47.e1. PubMed ID: 32593672
[TBL] [Abstract][Full Text] [Related]
19. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
Zhan H; Kaushansky K
Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.
Lee Tokar L; Crotty G; O'Keeffe D; Langabeer SE
Blood Cells Mol Dis; 2021 Sep; 90():102593. PubMed ID: 34217938
[No Abstract] [Full Text] [Related]
[Next] [New Search]
